NeurologyJohnson & Johnson
Johnson & Johnson Reports Positive Phase 3 Results for Nipocalimab in Generalized Myasthenia Gravis
BMI
Biotechnology Media Insights
Editorial Team · April 28, 2025
J&J announces positive Phase 3 Vivacity-MG3 trial results showing nipocalimab significantly reduces disease activity in generalized myasthenia gravis.
Johnson & Johnson today announced positive results from the Phase 3 Vivacity-MG3 trial evaluating nipocalimab in patients with generalized myasthenia gravis (gMG). The trial met its primary endpoint, demonstrating a significant reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.